Progress in Vertex talks bring cystic fibrosis drugs closer for Irish patients
Ireland’s Health Service Executive (HSE) has announced that its latest round of negotiations with US biotech firm Vertex Pharmaceuticals (Nasdaq: VRTX) were a success, bringing access to its drugs closer for cystic fibrosis (CF) patients.
The drugs involved are now expected to be available and reimbursed subject to the conclusion of contract negotiations, the finalization of logistical arrangements and the completion of the approval processes.
Orkambi (lumacaftor/ivacaftor) is set to be made available for CF patients aged 12 years and older who are homozygous for the F508del mutation in the CFTR gene, while those aged 18 years and older who have an R117H mutation in the CFTR gene will have access to Kalydeco (ivacaftor) film-coated tablets.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze